Latest stock price:
  • 2019-12-17Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China

    Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue”) has expandedits strategic partnership with Athenex, Inc. (Nasdaq: ATNX) to exclusively developand commercialize Athenex’s oncology product candidates Oral Paclitaxel (boththe capsule and the tablet formulations), Oral Irinotecan, as well as...

    see details >>
  • 2019-10-17XLifes once again named “top 50 biotechnology enterprises” of GAB

    Source: Guangdong Medical Valley On October 16, the second award ceremony for the “top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area "(“GBA")was held in Guangzhou. Xiangxue Life Sciences, Ltd (herein after referred to as “XLifes"), a subsidiary of Gua...

    see details >>
  • 2019-09-18Initiation of Phase I Clinical Study in China of KX2-361 Oral by XPH

    Link: BUFFALO, N.Y., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commer...

    see details >>
  • 2019-09-04Xiangxue & UM – To Build International Innovation Platform For TCM

    Date: 26-June-2019    Source:  MASTVNET ( Subject:Xiangxue & UM – To Build International Innovation Platform and Demonstration Base of Industrialization For TCM Cooperating with University of Macau, Xiang...

    see details >>
  • 目前在第1页, 共有3页, 共有9条记录 第一页 上一页 123 下一页 最后一页 跳转到

    No. 2, Jinfengyuan Road, Science City,
    Guangzhou Economic and Technological Development Zone


    XPH Group
    TCM Resources